The NLRP3 Inflammasome in Non-Alcoholic Fatty Liver Disease and Steatohepatitis: Therapeutic Targets and Treatment

Non-alcoholic fatty liver disease (NAFLD) is among the most prevalent primary liver diseases worldwide and can develop into various conditions, ranging from simple steatosis, through non-alcoholic steatohepatitis (NASH), to fibrosis, and eventually cirrhosis and hepatocellular carcinoma. Nevertheles...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Lili Yu, Wei Hong, Shen Lu, Yanrong Li, Yaya Guan, Xiaogang Weng, Zhiwei Feng
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Frontiers Media S.A. 2022-03-01
coleção:	Frontiers in Pharmacology
Assuntos:	NLRP3 inflammasome NAFLD NASH therapeutic agents
Acesso em linha:	https://www.frontiersin.org/articles/10.3389/fphar.2022.780496/full
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!